Prespecified=good and post-hoc=bad. This is how we as statisticians see it usually and I did too. However, over the past years, I realized more and more, that it’s not that easy.
How many details do you need to have to call an analysis pre-specified? Should we label a request to analyze a certain subgroup by regulators as well as a fishing expedition to find a significant subgroup both in the same way: post-doc?
Lovisa and I together with some others are presenting at the next PSI conference about this topic and today, we dive into this topic and identify different dimensions to be considered to understand better the different shades of pre-specified analyses.
Listen to this episode to avoid oversimplification and confusion in discussions in the future.
Featured courses
Click on the button to see our Teachble Inc. cources.
Lovisa Berggren
Director Statistics UCB (SSI launch team)
Lovisa Berggren (MSc), Senior statistical consultant, Freelancing consultant specializing in HTA submissions, data mining, and analyses of integrated clinical trials data. With a focus on Phase III and IV neuroscience, autoimmune, and oncology.
Lovisa gained her initial experience as a statistician working for 3.5 years with AstraZeneca. During this time she prepared and attended two public oral advisory committee meetings with the FDA and one EMA oral hearing for new indications with Quetiapine (neuroscience). Her job also included leading and coordinating big teams of statisticians and programmers under high pressure. After AstraZeneca Lovisa joined ImClone for 1.5 years as a contractor working on two phase III trials in oncology. During the restructuring and merger of ImClone and Eli Lilly Lovisa moved over to work as a contractor for Eli Lilly. During her 5.5 years with Lilly, she has worked with several data mining projects and publications (autoimmune and neuroscience). As well as in the role of lead statistician for the HTA submission of ixekizumab. Lovisa is currently working part-time for Eli Lilly and Cogitars.
In parallel, she conducting her PhD at the UMIT University in Austria. Her PhD thesis focuses on methods for evaluating the consistency of treatment effects in HTA reimbursement submissions.
Join The Effective Statistician LinkedIn group
This group was set up to help each other to become more effective statisticians. We’ll run challenges in this group, e.g. around writing abstracts for conferences or other projects. I’ll also post into this group further content.
I want to help the community of statisticians, data scientists, programmers and other quantitative scientists to be more influential, innovative, and effective. I believe that as a community we can help our research, our regulatory and payer systems, and ultimately physicians and patients take better decisions based on better evidence.
I work to achieve a future in which everyone can access the right evidence in the right format at the right time to make sound decisions.
When my kids are sick, I want to have good evidence to discuss with the physician about the different therapy choices.
When my mother is sick, I want her to understand the evidence and being able to understand it.
When I get sick, I want to find evidence that I can trust and that helps me to have meaningful discussions with my healthcare professionals.
I want to live in a world, where the media reports correctly about medical evidence and in which society distinguishes between fake evidence and real evidence.
Let’s work together to achieve this.
